Predict your next investment

HEALTHCARE | Biotechnology
prochon.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$3.95M

About ProChon Biotech

ProChon is a privately-held biotechnology company focused on modulating the fibroblast growth factor system to enable it to create more effective solutions for tissue regeneration. ProChon's products combine cell regeneration technologies with growth factors and biocompatible scaffolds to restore injured or chronically damaged tissues to normal. ProChon has filed patent applications, licensed patents for core technologies and products, and has been granted patents in the United States, Europe, Israel and Australia. ProChon's R&D facility resides in Ness Ziona, Israel and the executive management team is based in Woburn, Massachusetts.

ProChon Biotech Headquarter Location

Woburn, Massachusetts, 01801,

United States

Latest ProChon Biotech News

Histogenics Buys ProChon Biotech

May 18, 2011

Follow @luisarbeltran Boston Equity Advisors said Wednesday that they advised on Histogenics buy of ProChon Biotech. Financial terms were not announced. Histogenics, of Waltham, Mass., develops products to regenerate healthy cartilage. Investors includes  Boston Millennia Partners, Foundation Medical Partners, Altima Partners, Inflection Point Partners and a private investor. ProChon is an Israeli biotech that develops tissue-regeneration technology. PRESS RELEASE Boston Equity Advisors is pleased to announce that Histogenics Corporation has acquired ProChon Biotech Ltd., two regenerative medicine companies, in an all-stock transaction. Boston Equity Advisors served as the investment bank responsible for arranging the transaction. “This acquisition positions Histogenics with the immediate opportunity to unite tissue engineering technologies with cell therapy technologies to form a very robust portfolio of regenerative medicine technologies, products, intellectual property and industry management expertise. It is clear that the merging of the two companies will have significant impact on the global cartilage regeneration patient and surgeon community,” said Patrick O’Donnell, CEO of Histogenics. “The professional team at Boston Equity was instrumental in identifying the synergies between our two companies and brought the deal together. I thank them for their dauntless efforts.” “My congratulations go out to the management, board, investors and employees of Histogenics and ProChon,” commented Arnie Freedman of Boston Equity Advisors. “This is truly an exciting combination of product programs that will make a tremendous impact on healthcare and patient quality of life. We look forward to continuing our work with the two companies to ensure a smooth amalgamation and identify additional investors that want to be at the forefront of regenerative medicine technologies.” About Boston Equity Advisors Boston Equity Advisors, LLC focuses its investment banking and advisory activities on therapeutic medical technology. Boston Equity Advisors provides strategic, financing and transactional expertise to help management navigate the financial markets and implement strategy for success. Boston Equity Advisors has a track record of providing counsel to innovative life sciences companies seeking access to capital markets through private placements and mergers and acquisitions. www.boston-equity.com About Histogenics Histogenics develops and manufactures products that improve the body’s ability to regenerate healthy cartilage, improve joint function and prevent degenerative disease. Formed in 2000, the company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase I and Phase II clinical trials in which its NeoCart autologous tissue implant’s effectiveness is compared to that of standard microfracture surgery. Based in Waltham, Massachusetts, the company is privately held. Major investors include Boston Millennia Partners, Foundation Medical Partners, Altima Partners, Inflection Point Partners and a private investor. For more information, visit www.histogenics.com. About ProChon Biotech, Ltd. ProChon is a privately held Israeli biotechnology company focused on modulating the fibroblast growth factor system to enable it to create more effective solutions for tissue regeneration. ProChon’s products combine cell regeneration technologies with proprietary growth factors and biocompatible scaffolds to restore injured or chronically damaged tissues. ProChon has filed patent applications, licensed patents for core technologies and products and has been granted patents in the United States, Europe, Israel and Australia. © 2015 Buyouts Insider / Argosy Group LLC

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ProChon Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ProChon Biotech is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

ProChon Biotech Patents

ProChon Biotech has filed 16 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Bioinformatics
  • Conditions of the mucous membranes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/23/2015

1/9/2018

Clusters of differentiation, Transcription factors, Immune system

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/23/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

1/9/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Transcription factors, Immune system

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.